Targets › LEPR
3 programs from 3 companies in 11 trials: 5 Phase 3, 5 Phase 2, 1 Phase 4; Metabolic and endocrine, Psychiatry; next expected readout Jun 2027.
Receptor for hormone LEP/leptin (Probable). On ligand binding, mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade/FOS. In the hypothalamus, LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides,…. (UniProt, P48357)
Open in Phaseline: the race on LEPR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Amryt Pharma | Metreleptin Leptin receptor agonist | LEPR | Phase 4 | Partial Lipodystrophy | Feb 2028 |
| Regeneron Pharmaceuticals | Mibavademab Leptin receptor agonist | LEPR | Phase 3 | Monogenic Obesity; Generalized Lipodystrophy; Functional Hypothalamic Amenorrhea | Jun 2027 |
| Chiesi Farmaceutici | Metreleptin Leptin receptor agonist | LEPR | Phase 3 | Partial Lipodystrophy; Familial Partial Lipodystrophy; Lipodystrophy; Anorexia Nervosa … | Mar 2028 |
Partial Lipodystrophy (2) Monogenic Obesity (1) Generalized Lipodystrophy (1) Functional Hypothalamic Amenorrhea (1) Familial Partial Lipodystrophy (1) Lipodystrophy (1) Anorexia Nervosa (1) Diabetes (1) Lipomatosis, Multiple Symmetrical (1) Severe Insulin Resistance (1)
small molecule (2), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.